Who is sponsoring NCT01828892?

NCT01828892 is sponsored by Jinling Hospital, China.

What drugs are being tested in NCT01828892?

Interventions in NCT01828892: Endoscopy exploration and glue application, Endoscopy exploration, Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin), Nutrition support.

What condition does NCT01828892 study?

NCT01828892 studies Low-output External Gastrointestinal Fistula.

Is NCT01828892 still recruiting?

NCT01828892 is currently status unknown. Last updated 9 June 2015.

Last reviewed 2015-06-09 · How we verify

NCT01828892: FG-treatment

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Controlled Trial to Evaluate Fibrin Glue Application in the Treatment of Low-Output Enterocutaneous Fistulas

Status unknown NA Last updated 9 June 2015

What this trial tests

NA trial testing Endoscopy exploration and glue application in Low-output External Gastrointestinal Fistula in 30 participants. Status unknown.

Timeline

1 March 2014

Primary endpoint
1 June 2017

1 December 2017

Quick facts

Lead sponsor	Jinling Hospital, China
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 March 2014
Primary completion	1 June 2017
Estimated completion	1 December 2017
Sites	1 location across China

Drugs / interventions tested

Endoscopy exploration and glue application
Endoscopy exploration
Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin) — full drug profile →
Nutrition support

Conditions studied

Low-output External Gastrointestinal Fistula — all drugs for Low-output External Gastrointestinal Fistula →

Sponsor

Jinling Hospital, China

Who can join

Adults 18 to 65, any sex, with Low-output External Gastrointestinal Fistula. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Closure rates up to 14 days
Time frame: 14 days
The fraction of patients with complete closure of fistula during 14 days

Sponsor's own description

Adjuvant use of fibrin glue (FG) in the fistula tract has been shown to promote closure of low-output enterocutaneous fistulas (ECFs). The primary objectives of this study are to compare the clinical efficacy, safety of autologous platelet-rich fibrin glue (PRFG), commercial fibrin glue, and control therapy in the management of patients with low-output volume ECFs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluating the use of fibrin glue for sealing low-output enterocutaneous fistulas: study protocol for a randomized controlled trial.
Wu X, Ren J, Wang G, Wang J, et al · · 2015 · cited 7× · PMID 26445823 · DOI 10.1186/s13063-015-0966-9

Verify or expand the search:

Other Jinling Hospital, China trials

Trials by the same sponsor.

NCT07297238 — Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. · NA · recruiting
NCT07237542 — Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction · NA · recruiting
NCT07230314 — Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inh · Phase 2 · not yet recruiting
NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07124624 — Stepped-Wedge Cluster Randomized Trial of AI-Assisted CTA Detection for Intracranial Aneurysms in Regional Hospitals · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01828892 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jinling Hospital, China
Last refreshed: 9 June 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01828892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing